Author

W. F. da Silva

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. M. de Leal· 1 shared A. P. A. d. L. Lange· 1 shared D. A. Pereira-Martins· 1 shared E. D. R. P. Velloso· 1 shared E. Griessinger· 1 shared E. M. Rego· 1 shared G. d. S. Leandro· 1 shared G. Huls· 1 shared

Activity by Year

2022-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

A. M. de Leal

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy

K. Lima, D. A. Pereira-Martins, L. B. L. de Miranda, J. L. Coelho-Silva, G. d. S. Leandro, I. Weinhauser, R. d. C. Cavaglieri, A. M. de Leal, W. F. da Silva, A. P. A. d. L. Lange, E. D. R. P. Velloso, E. Griessinger, J. R. Hilberink, G. Huls, J. J. Schuringa, , J. A. Machado-Neto

This study shows that THZ-P1-2, a PIP4K2 inhibitor, kills leukemia cells by disrupting mitochondrial homeostasis and autophagy, with minimal effects on healthy cells.

bioRxiv · Aug 20, 2022Pharmacology & Toxicology